Federal prosecutors argue an industry amicus brief is irrelevant as a New York court weighs next steps in the MEV bot case against two brothers. The US government has filed a letter opposing the ...

VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy players, and the potential GLP-1 monetization upon US FDA approval. The ...